Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

3500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Glioma disease is the most common primary malignant tumor of the central nervous system, with an annual incidence of about 3-8 people per 100,000 population, of which glioblastoma with the highest degree of malignancy and the worst prognosis accounts for 70-75%. The construction goal of this project is to construct a multivariate retrospective glioma database (3000 cases) integrating clinical information, magnetic resonance imaging examination and molecular pathological results, and a prospective glioma database (500 cases) integrating advanced magnetic resonance sequences. It aims to form a standardized database integrating clinical-prognostic information, magnetic resonance imaging and pathological results. Based on the construction of the above standardized database, the specifications for the acquisition of cranial magnetic resonance images, the image segmentation and labeling process, and the expert consensus on database construction and use management of glioma diseases were established. Form a multimodal, large-capacity, high-quality, and rich medical imaging database that conforms to the characteristics of Chinese groups and clinical diagnosis and treatment norms; On this basis, the data are dynamically updated, in-depth mining, and the classification and grading standards of glioma diseases, prognosis judgment criteria and treatment efficacy evaluation system are formulated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study

NCT06002711

High-grade Glioma

RECRUITING

68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma

NCT01801371

Glioma

UNKNOWN EARLY_PHASE1

Visual Study of Molecular Genotype in Glioma Evolution

NCT03750890

Glioma of Brain

UNKNOWN

Study on Radiogenomics Features Associated With Radiochemotherapy Sensitivity in Gliomas

NCT06454097

Glioma

RECRUITING NA

Noninvasively Predicting Gene Status of Glioma

NCT03102112

Glioma of Brain

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Glioma disease is the most common primary malignant tumor of the central nervous system, with an annual incidence of about 3-8 people per 100,000 population, of which glioblastoma with the highest degree of malignancy and the worst prognosis accounts for 70-75%. The construction goal of this project is to construct a multivariate retrospective glioma database (3000 cases) integrating clinical information, magnetic resonance imaging examination and molecular pathological results, and a prospective glioma database (500 cases) integrating advanced magnetic resonance sequences. It aims to form a standardized database integrating clinical-prognostic information, magnetic resonance imaging and pathological results. Based on the construction of the above standardized database, the specifications for the acquisition of cranial magnetic resonance images, the image segmentation and labeling process, and the expert consensus on database construction and use management of glioma diseases were established. Form a multimodal, large-capacity, high-quality, and rich medical imaging database that conforms to the characteristics of Chinese groups and clinical diagnosis and treatment norms; On this basis, the data are dynamically updated, in-depth mining, and the classification and grading standards of glioma diseases, prognosis judgment criteria and treatment efficacy evaluation system are formulated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Molecular pathology of glioma positive

This study does not intervene in this process.

Intervention Type DIAGNOSTIC_TEST

This study does not intervene in this process.

Molecular pathology of glioma negative

This study does not intervene in this process.

Intervention Type DIAGNOSTIC_TEST

This study does not intervene in this process.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

This study does not intervene in this process.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1) a clear diagnosis of glioma based on pathological results;
* (2) The MRI sequence is complete and there are no obvious artifacts in the image;
* (3) The patient signs an informed consent form

Exclusion Criteria

* (1) Suffering from other neurological diseases;
* (2) Prior to enrollment, surgery or biopsy, or a history of radiation therapy or chemotherapy;
* (3) Unable to complete clinical scoring and related laboratory tests, unable to complete follow-up;
* (4) Unable to tolerate MRI examination; Poor image quality, such as motion artifacts.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes